Vancouver, BC – March 02, 2015 – InMed Pharmaceuticals, Inc. (“InMed”) (CSE: IN; OTCQB: IMLFF), announced today that Tarek Mansour, Ph.D., a veteran executive in the Life Science sector, and Kevin Puil, an experienced investment manager, have joined the company’s Board of Directors. Dr. Mansour has more than 26 years of experience in drug discovery and development, and has held senior leadership and management positions at leading biotechnology and pharmaceutical companies. Mr. Puil is an analyst and former hedge fund manager with 20 years experience managing investments. These strategic additions add significant expertise and insight to InMed as the company advances its clinical stage pipeline of novel therapies.
“We are pleased to welcome Dr. Mansour and Mr. Puil to our Board of Directors,” said Craig Schneider, President & CEO. “Dr. Mansour is a distinguished R&D executive and entrepreneur whose experience and expertise in both biotechnology and pharmaceutical drug development will be instrumental in guiding our strategic initiatives. As we continue along our accelerated growth trajectory, Mr. Puil’s expertise in finance and investments significantly strengthens InMed’s infrastructure. We look forward to leveraging their collective insight as we move forward.”
Dr. Mansour was previously with Xenon Pharmaceuticals as their Executive Vice-President. He also held similar positions at Pfizer and Wyeth Pharmaceuticals prior to founding Sabila Biosciences LLC, where he is currently the Chief Executive Officer.
Dr. Mansour’s expertise spans multiple therapeutic areas including anti-infectives, oncology, inflammatory, metabolic, cardiovascular and pain. Under his leadership, several compounds have progressed to various stages of clinical evaluation including FDA approvals and late stage development. Amongst these candidates are Epivir, Zeffix, Troxatyl, Bosulif, Neratinib and PFE384.
Dr. Mansour received a B.S. degree in Chemistry from the American University of Beirut, Lebanon (1977), M.Sc. in Chemistry from the University of Manchester Institute of Science and Technology, U.K. (1979), a Ph.D. degree from the University of Missouri-Columbia, U.S.A. (1982) and a diploma in Applied Management from McGill University, Canada (1993). Following postdoctoral tenure at the University of Ottawa, Dr. Mansour moved to McGill University in 1985 as a research associate in the Immunomedicinal Chemistry Chair.
Mr. Puil is currently a Managing Partner at a Private Equity fund based in California. Prior to that, he held senior positions at several firms including Bolder Investment Partners in Vancouver (now Haywood Securities), where he was a Partner and Portfolio Manager; and in San Francisco at Gissen & Associates as Portfolio Manager and the Encompass Fund as Senior Analyst. Kevin currently serves as a Board Director of two Toronto Stock Exchange companies. He holds a degree in Economics from the University of Victoria in British Columbia, and is a Chartered Financial Analyst (CFA) charterholder.
InMed is a clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed’s proprietary platform technology, product pipeline and accelerated development pathway are the fundamental value drivers of the company. For more information, visit www.inmedpharma.com
ON BEHALF OF THE BOARD
InMed Pharmaceuticals Inc.
President and Chief Executive Officer
E: [email protected]
Forward Looking Statements
This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities laws. Forward-looking information is based on management’s current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this news release includes statements about the use of net proceeds from the private placement and the expected fundamental value drivers of the company. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Known risk factors include, among others: InMed may not use net proceeds received from the private placement as currently contemplated and InMed’s proprietary platform technology, product pipeline and accelerated development pathway may not return their expected level of value.
A more complete discussion of the risks and uncertainties facing InMed is disclosed in InMed’s continuous disclosure filings with Canadian securities regulatory authorities at www.sedar.com. All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.